Frontage Holdings Corporation

Equities

1521

KYG3679P1019

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
1.31 ^HKD	-3.68%		-4.38%	-43.53%

Apr. 01	Frontage Holdings' Net Profit Plunges 59% in 2023	MT
Mar. 28	Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Frontage Holdings Corporation Announces Earnings Results for the Six Months Ended June 30, 2021

August 25, 2021 at 08:00 am EDT

Frontage Holdings Corporation announced earnings results for the six months ended June 30, 2021. For the six months, the company reported Revenue of USD 85.1 million compared to USD 50.7 million a year ago. Net Profit was USD 9.1 million compared to USD 4.5 million a year ago. Earnings per Basic share was USD 0.0043 compared to USD 0.0022 a year ago. Earnings per Diluted share was USD 0.0042 compared to USD 0.0021 a year ago.

Latest news about Frontage Holdings Corporation

Frontage Holdings' Net Profit Plunges 59% in 2023	Apr. 01	MT
Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Frontage CFO Resigns	Feb. 01	MT
Frontage Holdings Corporation Announces CFO Changes	Jan. 31	CI
Great Portland Estates cautiously optimistic thanks to London projects	Jan. 23	AN
Frontage Holdings Corporation Announces the Appointment of Henry Gao as President of Asia Pacific	Jan. 02	CI
Frontage Logs $5.2 Million in Q3 Profit	23-10-27	MT
Frontage Holdings Corporation commences an Equity Buyback Plan for 205,675,391 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	23-08-28	CI
Tranche Update on Frontage Holdings Corporation's Equity Buyback Plan announced on June 2, 2022.	23-08-25	CI
Frontage Holdings Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Frontage Holdings' Canadian Unit to Buy Nucro Technics	23-08-16	MT
Frontage Holdings Corporation's Equity Buyback announced on June 2, 2022, has expired with 26,922,000 shares, representing 1.31% for HKD 70.18 million.	23-05-24	CI
Unibail-Rodamco-Westfield Acquires Hammerson's Stake in UK Portfolio	23-04-26	MT
Unibail-Rodamco-Westfield Completes 50% Stake Acquisition in South London Property	23-04-25	MT
Tiffany, now owned by LVMH, reopens on a Fifth Avenue in flux	23-04-24	RE
Great Portland Estates leases final retail unit at Oxford Street asset	23-04-03	AN
Tranche Update on Frontage Holdings Corporation's Equity Buyback Plan announced on June 2, 2022.	23-03-28	CI
Frontage Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Silo Pharma Shares Rise 12% After Positive Results for SP-26 Study	23-03-15	DJ
Frontage Names CEO	23-01-03	MT
Frontage Holdings Corporation Announces Change of Chief Executive Officer	23-01-03	CI
Sing Tao News to Sell Commercial Building in Toronto, Canada, for Over $5 Million	22-09-22	MT
Frontage Announces Opening of Custom-Built Laboratory Facility in Hayward, CA	22-09-21	CI
Frontage Holdings Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Frontage Holdings Corporation Announces Change of Address of Principal Place of Business in Hong Kong	22-08-15	CI

Chart Frontage Holdings Corporation

Duration

Period

More charts

Company Profile

Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the People's Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Frontage Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1673 USD

Average target price

0.2178 USD

Spread / Average Target

+30.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FRONTAGE HOLDINGS CORPORATION	-43.53%	351M
IQVIA HOLDINGS INC.	-2.04%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.94%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.55%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.96%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.30%	11.68B
MEDPACE HOLDINGS, INC.	+20.67%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.19%	11.15B

Other Biotechnology & Medical Research